Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
09 avr. 2024 08h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29 mars 2024 08h21 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28 mars 2024 08h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Provides Interim Update
04 mars 2024 08h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
08 févr. 2024 17h55 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
13 nov. 2023 16h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
02 nov. 2023 16h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
Molecular Templates to Participate in Upcoming Investor Conferences
01 nov. 2023 16h12 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
28 sept. 2023 16h11 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics...
Molecular Templates Announces 1-for-15 Reverse Stock Split
11 août 2023 11h22 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with...